Pfizer Inc. (PFE) Shares Sold by Stifel Financial Corp
Stifel Financial Corp lowered its holdings in Pfizer Inc. (NYSE:PFE) by 0.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,322,991 shares of the biopharmaceutical company’s stock after selling 7,380 shares during the quarter. Pfizer comprises approximately 0.9% of Stifel Financial Corp’s investment portfolio, making the stock its 10th largest holding. Stifel Financial Corp owned about 0.12% of Pfizer worth $245,852,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Shine Investment Advisory Services Inc. bought a new position in Pfizer during the 2nd quarter valued at $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer during the 2nd quarter valued at $103,000. D. Scott Neal Inc. lifted its stake in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer during the 1st quarter valued at $121,000. Finally, Herndon Capital Management LLC bought a new position in Pfizer during the 2nd quarter valued at $120,000. 69.89% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares in the company, valued at approximately $4,186,450.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders sold a total of 60,280 shares of company stock worth $2,118,988 over the last 90 days. 0.06% of the stock is currently owned by company insiders.
Several equities analysts have weighed in on PFE shares. Cowen set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Berenberg Bank restated a “hold” rating and set a $36.00 price objective (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Jefferies Group restated a “hold” rating and set a $35.00 price objective on shares of Pfizer in a research note on Friday, August 18th. BMO Capital Markets reiterated a “buy” rating and set a $37.00 target price on shares of Pfizer in a research note on Wednesday, September 6th. Finally, Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research note on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $38.77.
Pfizer Inc. (PFE) traded up $0.24 during midday trading on Friday, hitting $35.74. The stock had a trading volume of 14,900,000 shares, compared to its average volume of 14,347,659. The company has a market cap of $213,035.67, a PE ratio of 14.30, a price-to-earnings-growth ratio of 2.52 and a beta of 1.01. Pfizer Inc. has a 12 month low of $30.90 and a 12 month high of $36.78. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the previous year, the business posted $0.61 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. equities research analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date was Thursday, November 9th. Pfizer’s dividend payout ratio is currently 79.01%.
ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Shares Sold by Stifel Financial Corp” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/pfizer-inc-pfe-shares-sold-by-stifel-financial-corp/1755977.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.